Clinical Trial Update: Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil [Phase 3]

View source ↗

Summary

An extension Phase 3 study is evaluating the long-term safety of dry powder inhaled treprostinil (LIQ861) in patients with pulmonary arterial hypertension; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• LIQ861 (treprostinil)

Snippet

Sponsor: Liquidia Technologies, Inc. | Conditions: Primary Pulmonary Hypertension | Phase 3 | Status: ACTIVE_NOT_RECRUITING